- US Bonds Pare Losses After 7-Year Auction
- New-Home Sales Jump to Highest Level in Over Year
- Judge Erases Couple's $525,000 Mortgage Payment
- Claims Level Suggests End to Job Losses
- Consumers Catching the Holiday Spirit
- Airlines Hit With Penalties for Stranding Passengers
- Consumer Mood Improves, but Anxiety Over Finances
- Jobless Claims Below 500,000, Durable Orders Slip
- US Said It Will Reduce Emissions by 17% by 2020
- It's Beginning To Look A Lot More Riskless
- Crescenzi: Claims Level Suggests End to Job Losses
- Hedge Funds Take Early Lead in Warren Buffett's 'Big Bet'
- S&P Stocks Trading at New 52-Week Highs
- 4 Food Stocks to Stuff in Your Portfolio: Analyst
- S&P at 1050-1200 Trading Range Next Year: Strategist
- Treasury On Mortgage Modifications
- Blue Jeans Expected to See Another Green Christmas
- Investors Thankful for Gains This Year
MOST SHARED
- Ritz-Carlton ?Struggling? in the US: President
- Garlic Price Rises Surpass Gold, Stocks in China
- Half of Banks' Losses May Still Be Hidden: IMF Head
- New-Home Sales Jump 6.2% To Highest Level in Over Year
- Oil Price to Average $75.40 in 2010: Poll
- Jobless Claims Below 500,000, Durable Orders Slip
- Americans Ditch Planes for Trains this Thanksgiving
- The 'Real' Jobless Rate: 17.5% Of Workers Are Unemployed
- Consumer Mood Improves, But Anxiety Over Personal Finances
Text Size 
Dendreon [DNDN
Loading...
()
] shares surged after three members of Congress asked for an investigation of a Food and Drug Administration panel's vote against the pharmaceutical company's prostate cancer drug.
The congressional trio asked Rep. John Dingell, chairman of the House Energy and Commerce Committee, to probe allegations of conflicts of interest and ethical violations of at least two FDA advisory committee members that opposed approval of Provenge.
There was no word from Dingell's office on whether the investigation will proceed, but investors sent Dendreon shares up 18 percent following a CNBC report on the matter.
A spokesperson for Dendreon said it had no comment.
The House Energy and Commerce Committee had not yet received the Congressmen's letter, a spokesperson said Thursday afternoon. If it does, the committee will review the request and decide whether to launch an investigation or hold a hearing, the spokesperson said.
Print
Email
- Here's how key provisions of the health care reform bill would impact your insurance and how you'll pay for it.
- Remember when auto shows were major events where new models could generate buzz?
- It may be the most unusual guide to business you'll read.
- After nine years the NBA’s minor league equivalent is finally coming into its own.
- Bill Griffeth is taking a leave of absence from CNBC and Power Lunch for a year. Here's a message from Bill.
- For nearly three decades, these on-call experts have been dishing advice on how to – and not to – cook turkey.
Data is a real-time snapshot *Data is delayed at least 15 minutes